Biogen, the co-developer of Aduhelm (aducanumab) has submitted the final protocol for ENVISION — the Phase 4 post-marketing study of the therapy in early Alzheimer’s disease — to the U.S. Food and Drug Administration (FDA) for review and approval, the company has announced. Screening of the first patient is expected in May, according to Biogen’s press…
Black people with multiple myeloma live longer than white patients with similar disease symptoms when both receive the same new and updated medical treatments, according to an analysis of the Surveillance, Epidemiology, and End Results (SEER) database. However, Black myeloma patients were less likely to receive such novel treatments than white individuals — even when…
Prothena has begun testing single ascending doses (SAD) of PRX012, its investigational anti-amyloid beta antibody therapy, in a Phase 1 clinical trial with healthy volunteers and people with Alzheimer’s disease. This follows the recent approval of the company’s investigational new drug (IND) application for PRX012 by the U.S. Food and Drug Administration. A next-generation antibody,…
Most adults in the U.S., as well as many doctors, have difficulty distinguishing between the early stages of Alzheimer’s disease and cognitive changes due to normal aging, according to the latest annual report from the Alzheimer’s Association. The report draws on responses to surveys, one of adult Americans and another of primary care physicians in the…
A dual vaccine targeting both amyloid plaques and tangled fibers made up of tau — two abnormal protein aggregates that build up in the brain of those with Alzheimer’s — may have potential to treat and prevent the disease. Prothena, its developer, has found preclinical evidence that the vaccine drives the generation of a sufficient…
Atuzaginstat (COR388), Cortexyme’s investigational oral therapy, effectively suppressed the activity of its target — toxic enzymes called gingipains — and was associated with reductions in several disease biomarkers in people with mild-to-moderate Alzheimer’s, according to updated data from the Phase 2/3 GAIN clinical trial. Similar to previously reported findings, these benefits were most pronounced among patients…
Aduhelm (aducanumab) continues to clear away amyloid plaques and tangled fibers made up of tau — two abnormal protein aggregates that build in the brain of those with Alzheimer’s disease — after nearly two and a half years of treatment, Biogen, which markets the treatment, reports. It also announced plans to begin patient screening for ENVISION,…
Even if they’re fully vaccinated, multiple myeloma patients still have an increased risk of COVID-19 infection compared with people without cancer, according to a study looking at data from more than 500,000 individuals in the U.S. Called breakthrough infections, these post-vaccination illnesses from SARS-CoV-2 — the virus that causes COVID-19 — also were associated with…
AEV103 (3,6’-dithiopomalidomide), a potentially immunomodulating medicine, was able to quell brain inflammation and slow cognitive decline in a mouse model of Alzheimer’s disease, a study has found. The medicine, developed originally at the National Institutes of Health (NIH) and now licensed to AevisBio, exerted its effects even in the absence of any change in the…
The National Institute on Aging has awarded $2.85 million in funding to a research team from the University of Tennessee Health Science Center (UTHSC) to study the role of mitochondria — cells’ powerhouses — in age-related diseases, such as Alzheimer’s. The five-year funding will support a project called “The interaction effects of genetic variants, age,…
